SJP-002C | Clinical Trials | Global Access & Affordability
One year ago, we filed a provisional patent application for our Upper Respiratory Infection Therapeutic – SJP-002C, covering the novel manufacturing process for our dual-acting oral therapy. This filing established an early priority date while allowing time to develop supporting data. We are now transitioning to the non-provisional phase, the formal examination stage by the USPTO. This critical step also gave us the opportunity to add new data to fortify our claims.
KVK Tech recently completed our 3-month FDA submission batch stability results—now included in our non-provisional application—demonstrating exceptional performance under both accelerated and long-term conditions.
These real-world results validate the robustness of our formulation and enhance the strength and defensibility of our patent claims.
Adding the stability data to the patent significantly enhances its value by demonstrating unexpected and superior performance over prior formulations, thereby strengthening arguments for novelty and non-obviousness. It provides concrete, real-world evidence supporting the claims, making the patent more defensible against challenges and more attractive for licensing, acquisition, and regulatory approval. The data also highlights key commercial advantages—such as extended shelf-life, reduced impurities, and optimized manufacturing processes—which increase the patent’s marketability, raise its potential valuation, and improve the likelihood of securing exclusivity extensions and premium pricing in the marketplace.
